ACELYRIN
Latest round
- Series C
Last raised
- Sep 2022
Total raised
- $550M
Investors
- 13
About ACELYRIN
Based in California, US, and founded in 2020 by Shao-Lee Lin and Robert F. Carey, ACELYRIN, Inc. is a biopharma company that acquires, identifies, and accelerates the commercialization and development of drug therapies for patients with immunologic diseases. In May 2023, ACELYRIN, Inc. The company is developing izokibep, which is a unique antibody mimetic and potent interleukin-17A (IL-17A) inhibitor for the treatment of uveitis, axial spondyloarthritis, hidradenitis suppurativa (HS), and psoriatic arthritis.
Who invested in ACELYRIN
13 investors across 3 rounds
See all investors in ACELYRIN
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ACELYRIN
Who invested in ACELYRIN?
ACELYRIN has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ACELYRIN raised?
ACELYRIN has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ACELYRIN last raise money?
ACELYRIN's most recent round on record is a Series C, in Sep 2022.
What does ACELYRIN do?
Based in California, US, and founded in 2020 by Shao-Lee Lin and Robert F.
Where is ACELYRIN headquartered?
ACELYRIN is headquartered in Agoura Hills, US.
Which VCs invest in companies like ACELYRIN?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ACELYRIN's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like ACELYRIN? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.